MINERALYS THERAPEUTICS, INC. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- MINERALYS THERAPEUTICS, INC. stock issued during period, value, new issues for the quarter ending 2025-06-30 was $9.50M.
- MINERALYS THERAPEUTICS, INC. stock issued during period, value, new issues for the quarter ending 2025-03-31 was $188.74M, a 62.63% increase year-over-year.
- MINERALYS THERAPEUTICS, INC. stock issued during period, value, new issues for the quarter ending 2024-03-31 was $116.06M, a 42.36% decline year-over-year.
- MINERALYS THERAPEUTICS, INC. stock issued during period, value, new issues for the quarter ending 2023-03-31 was $201.36M.
- MINERALYS THERAPEUTICS, INC. stock issued during period, value, new issues for fiscal 2024 was $116.06M, a 42.36% decline from fiscal 2023.
- MINERALYS THERAPEUTICS, INC. stock issued during period, value, new issues for fiscal 2023 was $201.36M.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2025-06-30 | $9.50M 10-Q · filed 2025-08-12 | |
| 2025-03-31 | $188.74M 10-Q · filed 2025-08-12 | |
| 2024-12-31 | $116.06M 10-K · filed 2026-03-12 | |
| 2024-03-31 | $116.06M 10-Q · filed 2025-11-10 | |
| 2023-12-31 | $201.36M 10-K · filed 2025-02-12 | |
| 2023-03-31 | $201.36M 10-Q · filed 2024-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |